• No products in the cart.

ISCTR Donation

Personal Info

Credit Card Info
This is a secure SSL encrypted payment.
Billing Details


Donation Total: $100.00

  • No products in the cart.

ISCTR Donation

Personal Info

Credit Card Info
This is a secure SSL encrypted payment.
Billing Details


Donation Total: $100.00

  /  Governing Board


Nabil Dib, MD, MSc, FACC

President, USA

Dr. Nabil Dib, M.D., MSc, FACC is one of the world’s most renowned cardiovascular researchers and doctors. He completed his Interventional Cardiology Fellowship Program at Harvard Medical School, Beth-Israel-Deaconess Medical Center in Boston. Dr. Dib also completed an additional year in Investigational Devices at Harvard Medical School. Additionally, he continued his education at Harvard School of Public Health, where he obtained a degree in Master of Science in Epidemiology and Research, concentrated on a clinical trial designed and effectiveness.

He is an Associate Professor of Medicine and Director of Clinical Cardiovascular Cell Therapy, at University of San Diego, Director of Cardiovascular Stem Cell Consultants and Heart Sciences Center, President and Founder of the International Society for Cardiovascular Translational Research (ISCTR) and Founder and Editor in Chief of the Journal of Cardiovascular Translational Research.

For more than 13 years, Dr. Dib has been conducting research and developing the newest investigational treatments for advanced cardiovascular disease. He is internationally known and respected for his research and work regarding the use of adult stem cells to restore the health of patients with severe heart disease.

Dr Dib is currently the Director of Cardiovascular Research for Mercy Gilbert and Chandler Hospitals in Gilbert, Arizona.


Anthony DeMaria, MD, FACC

Vice-President, USA

Dr. DeMaria is the Judith and Jack White Chair in Cardiology and founding director of the Sulpizio Cardiovascular Center at UCSD. He regularly participates in trials involving non-invasive methods to diagnose and treat heart disease.

Dr. DeMaria has received numerous awards and is listed in The Best Doctors in America. He served as a member of the Subspecialty Board on Cardiovascular Disease for the American Board of Internal Medicine from 1991 to 1997. Dr DeMaria was past president of the American College of Cardiology, and the youngest president to serve the College to date.

He is the Editor in Chief of the Journal of American College of Cardiology and Echocardiography. He serves on the editorial boards and acts as editorial consultant for almost 30 medical journals. He is the Director of ISCTR Scholarship Program at University of California San Diego.



Professor Sir Magdi Yacoub, MD, FRS, FACC

International Liaison, London

Professor Sir Magdi Yacoub, MD, FRS is reputed to have performed more heart transplants than anyone else in the world having restarted the transplant program at the Harefield in 1980. The Harefield has now performed over 2500 transplants. He is currently Professor of Cardiothoracic Surgery at Imperial College in London, leading over 60 researchers in tissue engineering, myocardial regeneration, stem cell biology, end stage heart failure and transplant immunology. He is the International Liason for the International Society for Cardiovascular Translational Research.

Dr. Yacoub is also well known for his charity work and was Knighted by Queen Elizabeth in 1991. In 1995 he founded the charity Chain of Hope, which has funded new heart surgery hospitals for children who would otherwise never get surgery in countries including Egypt, Ethiopia, Jamaica and Kenya. Dr. Yacoub leads teams of volunteers traveling to the Chain of Hope hospitals to provide training and expertise.


Yacoub’s major achievements may be summarized:

  • establishing heart transplantation in UK and becoming the world’s leading transplant surgeon
  • establishing and becoming a master of the “Ross Procedure” or pulmonary autograft, including a randomised control trial
  • pioneering the modern arterial switch operation
  • promoting the use of left ventricular assist devices for the ‘Bridge to Recovery’ and establishing the largest experience in the world
  • establishing the Heart Science Centre, Magdi Yacoub Institute for research into the causes and treatment of cardiac disease
  • establishing the Chain of Hope Charity which provides cardiothoracic surgical care to the developing world
  • championing academic medicine, humanitarian surgery and becoming an example of a minority surgeon who flourished in institution-dominated field.

He was involved in the restart of UK heart transplantion in 1980 (there had been moratorium following the series of three performed by Donald Ross in 1968), carried out the first UK live lobe lung transplant and went on to perform more transplants than any other surgeon in the world. A 1980 patient, Derrick Morris, was Europe’s longest surviving heart transplant recipient until his death in July 2005. A March 1978 heart by-pass patient continues to live a very active and fruitful life.



Spencer B. King, III, MD, FACC

Chairman, Education and Publications Committee, USA

Spencer B. King, III, MD, MACC, FSCAI, FESC, President of the Heart and Vascular Institute at Saint Joseph’s Hospital.

Dr. King has directed invasive and interventional cardiology training for more than 150 cardiology Fellows. He began his career at Emory University Hospital, where he served as director of the Cardiac Catheterization Laboratory from its inception through 2000 and was director of interventional cardiology and the Andreas Greuntzig Cardiovascular Center at Emory University from 1985 until 2000.

Dr. King was president of the American College of Cardiology, President of the Society for Cardiac Angiography and Interventions and served as Chair of the Interventional Cardiology Boards of the American Board of Internal Medicine. Dr. King is the author of more than 500 papers on cardiology, has edited or co-edited ten books including the recently released text book, Interventional Cardiology. He is editor in chief of the Journal of the American College of Cardiology: “Cardiovascular Interventions.” He is also Director of Education for International Society for Cardiovascular Translational Research (ISCTR) and Director of Education for ISCTR Scholarship Program at Emory University.


Robert Roberts, MD, FACC

Chairman, Governance/Nominating Committee, Canada

Dr Robert Roberts was appointed President, Chief Executive Officer and Chief Scientific Officer of the University of Ottawa Heart Institute in 2004. He is also Director of the Ruddy Canadian Cardiovascular Genetics Centre at the Heart Institute and retains an Adjunct Professorship of Medicine at Baylor College of Medicine in Houston, Texas.

Dr. Roberts is a major national and international educator and spokesman for molecular genetics and currently serves on the Board of Directors of the Ontario Genomics Institute; the Board of Directors of the Fields Institute, Research in Mathematical Sciences, the Medical Advisory Board for the Gairdner Foundation; and Board of Directors for the International Society for Cardiovascular Translational Research spearheading the Nomination of Scholarship.

Dr. Roberts received his MD from Dalhousie University in Halifax and completed his Residency in Internal Medicine and Fellowship in Cardiology at the University of Toronto. Funded by a Canadian Heart Foundation Scholarship, he pursued research in enzymology and cardiac metabolism at the University of California, San Diego, following which he was Director of the Cardiac Care Unit at Barnes Hospital in St. Louis, Missouri, and Associate Professor of Medicine at Washington University. In 1982, he assumed the position as Chief of Cardiology at Baylor.

On moving to the Heart Institute, he founded the Ruddy Canadian Cardiovascular Genetics Centre, where he initiated a large multicentre study in pursuit of genes responsible for coronary artery disease. In recognition of this effort, Dr. Roberts and his co-investigators were awarded a $12 million grant by the Canada Foundation for Innovation in 2006.

Dr. Roberts has held several leadership roles with the National Institutes of Health: He was involved in the Cardiovascular Study Section of the Cardiology Advisory Committee and Advisory Council in 2000 to 2001. Similarly, he has played an active leadership role with the AHA, including serving as Chair of the Study Section for Physiology and Pathophysiology; Member of the National Scientific Sessions Committee; Vice Chair and Chair of the Research Planning Evaluation Committee; Member of the Board of Directors and Vice President. For the ACC, he has served as Chair of the Scientific Sessions; Member of the Board of Trustees; and Chair of the Grant Review Section.


The Honorable Peter Barca

Secretary, USA

Peter Barca earned his undergraduate degree from the University of Wisconsin-Milwaukee. He attended Harvard Graduate School and went on to earn an M.A. in public administration and educational administration from the University of Wisconsin-Madison in 1983.

Barca entered politics in 1985 when he won his first election to the State Assembly, succeeding Joseph Wimmer in the 64th District. The 64th District much of the City of Kenosha and portions of the City of Racine, Town of Somers, Village of Mount Pleasant and Village of Elmwood Park.

In early 1993, President Bill Clinton appointed U.S. Representative Les Aspin to the post of Secretary of Defense, and a special election was called to fill Wisconsin’s 1st Congressional District. Barca faced perennial Republican challenger Mark Neumann and won election to the House of Representatives in the 103rd Congress.

President Clinton appointed Barca to serve as Midwest Regional Administrator to the U.S. Small Business Administration. He also served as National Ombudsman to the SBA.

Barca was also leader of the National Regulatory Fairness Program, an initiative which included more than fifty company presidents throughout the country aimed at making regulatory enforcement small business friendly. Peter serves as Secretary for the International Society for Cardiovascular Translational Research.


David R. Holmes, Jr., MD, MACC

Board of Directors, USA

Dr. Holmes is currently a Professor of Medicine at the Mayo Clinic College of Medicine and a consultant in the Division of Cardiovascular Diseases and the Department of Internal Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Holmes has also been named the Edward W. and Betty Knight Scripps Professor in Cardiovascular Medicine in Honor of Dr. George M. Gura, Jr. He was awarded an Honorary Fellowship of the Royal College of Physicians in Ireland in November 2011. He has received the Distinguished Scientist Award (Clinical Domain) from the American College of Cardiology and the Research Career Achievement Award from the Mayo Graduate School of Medicine. He is a Past President of the American College of Cardiology (ACC) as well as the Society for Cardiac Angiography and Interventions (SCAI). He has lectured widely both nationally and internationally. He has received the Herrick Award from the American Heart Association.

His special areas of interest include acute coronary syndromes, interventional cardiology, restenosis, vascular biology, and risk outcomes analysis. In addition, he has been involved in the development of new catheter designs for stroke prevention using left atrial appendage occlusion technology. He has been involved with the introduction and dispersion of transcatheter aortic valve replacement in the United States working with both ACC and the Society for Thoracic Surgery (STS). As part of that, he has been involved with regulatory agencies including FDA and CMS. Finally, he is involved in the development of continued application of percutaneous coronary intervention technology to noncoronary vascular beds.

Dr. Holmes received his medical degree at Medical College of Wisconsin in Milwaukee and completed his internship at Virginia Mason Hospital in Seattle. He also served in the United States Navy at the National Naval Medical Center in Bethesda.


Oliver Harper, MD

Chairman, Public Awareness and Sustainability Committee, USA

Oliver Harper, MD, Family Medicine and Geriatrics.

1970 Graduate of Creighton University School of Medicine.

Co Founder Arizona Medical Clinic, now Banner Arizona Medical Clinic,
100 plus physician multi specialty group in Maricopa County Arizona.

Past Board Member and Chief of Staff Boswell Hospital, Sun City, Arizona.

Volunteer Physician in Kenya, East Africa, Dominican Republic and various Arizona clinics for the underserved.

Lecturer University of Arizona College of Medicine Phoenix Doctoring Program.

Board Member ISCTR, St. Joseph Hospital Foundation Phoenix, Experience
Matters, Past Chairman Creighton University College of Medicine Alumni Advisory Board.

Finance Committee McCain 2008 Presidential Campaign.

Married to Sharon Culhane Harper with 5 children.


Mitchell W. Krucoff, MD, FACC

Board of Directors, USA

Dr. Krucoff is the Founder and Director of the Electrocardiology Core Lab at Duke Clinical Research Institute (DCRI), where he directs its interventional device trials, as well as Co-Director of DCRI’s Cardiovascular Devices Group. He also is Professor of Medicine at Duke Medical Center and directs the Cardiovascular Laboratory at the Durham Veterans Affairs Medical Center. Dr. Krucoff came to the DCRI in 1988 from Georgetown University.

He sits on the Board of Directors of the Sri Satya Sai Institute of Higher Medical Sciences in Puttaparthi, India; is senior editor of the Journal of Alternative & Complementary Medicine; and is past editor-in-chief of Alternative Therapies in Health & Medicine. He also is a fellow of the American College of Cardiology and the American College of Chest Physicians, and sits on the National Heart, Lung, and Blood Institute’s Clinical Trials Review Committee and the FDA’s Circulatory Devices Advisory Panel.

Dr. Krucoff’s research and clinical interests include acute coronary syndromes, asymptomatic myocardial ischemia, cardiac devices, eECG technologies, and cardiovascular applications of spiritual and complementary therapies.

After receiving his medical degree from George Washington University School of Medicine and Health Sciences, Dr. Krucoff completed his internal medicine internship at George Washington University Hospital and cardiology residency at Georgetown University Hospital.



Stefanie Dimmeler, PhD

Board of Directors, Germany

Stefanie Dimmeler is Director of the Institute of Cardiovascular Regeneration, Centre of Molecular Medicine, Goethe University Frankfurt, Germany, and Chief Editor of EMBO Molecular Medicine. Stefanie is the winner of the 1.55 million euro 2005 Leibniz Prize, received her graduate and Ph.D. degree in molecular cardiology at the University of Konstanz. She then completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the University of Frankfurt. She is professor of Experimental Medicine and head of the Section of Molecular Cardiology at the University of Frankfurt since 2001. She is author of more than 120 papers, all of which published in highly qualified journals, including Nature, Circulation, Circulation Research, and Blood. She serves on the Board of Directors for the International Society for Cardiovascular Translational Research.

Stefanie has been investigating basic mechanisms of endothelial cell biology and endothelial progenitor cells but also tackling clinically oriented projects in vascular biology. She has been focusing on cell therapy approaches for the treatment of ischemic heart disease and the research culminated in ongoing clinical trials of cardiovascular repair with human progenitor cells. More recently, she has concentrated on micro RNA-based therapeutics for cardiovascular disease.



Stuart D. Flynn, MD

Board of Directors, USA

Stuart D. Flynn, M.D., is the founding dean of Fort Worth’s new M.D. school, the TCU and UNTHSC School of Medicine. Pending accreditation from the Liaison Committee on Medical Education (LCME), the school will begin in July 2019.

He most recently served as founding dean of the University of Arizona College of Medicine – Phoenix. Previously, he was a professor of pathology and surgery at Yale University School of Medicine as well as an accomplished researcher, director of the residency program, a leader in the design and oversight of the school’s curriculum, and founding member of The Society of Distinguished Teachers at Yale.<!–?p > <p>Flynn received his medical degree and residency training from the University of Michigan and completed a fellowship in oncologic pathology at Stanford University.</p> <p>Flynn has authored more than 100 articles, books and monographs. He has received numerous honors including America’s Top Physician’s Award from the Consumers’ Research Council of America, the Bohmfalk Teacher of the Year Award from Yale University School of Medicine and the Averill A. Liebow Award for excellence in the teaching of residents, also at Yale. He has been a member of the National Board of Medical Examiners Pathology Test Committee and USMLE Step I Test Material Development Committee.


Daniel Burkhoff, MD, PhD

Board of Directors, USA

After earning a Bachelors of Sciences degree from Cornell University in Applied and Engineering Physics, Dr. Burkhoff obtained Doctor of Philosophy and Medical degrees from The Johns Hopkins School of Medicine and completed a fellowship in Cardiology at The Johns Hopkins Hospital. Dr. Burkhoff then moved to Columbia University in the City of New York where he established and ran the Cardiovascular Research Laboratory through 2003 and then the Director of the Jack Skirball Center for Cardiovascular Research of the Cardiovascular Research Foundation through 2005. He then focused on development and research of medical devices in his capacity as Medical Director of several startup companies including, most recently, CircuLite which was recently acquired by HeartWare. Dr. Burkhoff is also Adjunct Associate Professor of Medicine at Columbia University Medical School. Dr. Burkhoff is the author of many original articles, invited reviews and book chapters on cardiology spanning his research interests in basic and clinical aspects of ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure, including left ventricular assist devices. He is also author of Harvi, an interactive simulation-based educational mobile application available for the iPad for teaching ventricular mechanics and hemodynamics.



Charles Alison Simonton, MD, FACC, FSCAI

Board of Directors, USA

Charles Alison Simonton, MD, FACC, FSCAI

Chief Medical Officer
Abbott Vascular

Dr. Charles (Chuck) Simonton grew up in North Carolina and graduated from UNC-Chapel Hill with a B.A. in Chemistry. He received his MD degree from Harvard Medical School in 1980. This was followed by internship, residency and then chief residency in the Department of Internal Medicine at the University of California, San Francisco under the Chairmanship of Lloyd H. Smith, Jr. He was a cardiology fellow at Duke University Medical Center, completing clinical training and research in congestive heart failure and interventional cardiology. This was followed by 2 years as Assistant Professor of Medicine and Cardiology at Duke University Medical Center. In 1988, he took a position as an interventional cardiologist at the Sanger Clinic in Charlotte, NC and as Associate Professor of Medicine, UNC Medical School. He founded the Division of Cardiovascular Research at the Carolinas Heart Institute and the Carolinas Cardiovascular Foundation (CCVF) for the purpose of research and education in cardiovascular diseases. He also founded and directed the Advanced Cardiovascular Interventions (ACI) symposium in 1992, which grew consistently through its 17 year history.

In 2007, Dr. Simonton accepted the position of Chief Medical Officer and Divisional Vice President of Global Medical Affairs for Abbott Vascular. His role with Abbott Vascular includes evaluating and testing new internal devices in development; advising pre-market clinical research across clinical science, legal and regulatory groups; defining the global strategy and structure of all post-market clinical research; assessing new business development opportunities; medical oversight of commercial product performance and safety; and continuing his interest in the education of interventional vascular physicians by establishing a diversified medical sciences department. He is active in all strategic aspects of Abbott Vascular’s mission to bring the best therapeutic devices to patients through innovative technology development and comprehensive clinical research.



Stanton J. Rowe

Board of Directors, USA

Corporate Vice President, Advanced Technology
Chief Scientific Officer
Edwards Life Sciences

Stanton J. Rowe has been chief scientific officer since 2008 and also serves as corporate vice president, advanced technology. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technologies, a company he helped to found in 1999 and of which he served as president and CEO. Previously, Rowe was corporate vice president of business development and strategic planning for Datascope and was vice president of business development for Johnson & Johnson’s interventional systems division (JJIS) in Warren, New Jersey, responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research and marketing groups. Rowe joined Cordis after previously holding several positions in product management for a number of medical device companies. He is on the board of directors of InSeal Medical, Ltd. He is also on the board of directors for the Discovery Science Center in Orange County, as well as on the advisory boards for the engineering or biomedical engineering schools at UC Irvine, Georgia Tech and Brown University. Rowe received a bachelor’s degree from the University of Alabama.



Mark J. Toland

Board of Directors, USA

Mark J. Toland
Senior Vice President
Corporate Accounts and Healthcare Solutions

Mark Toland leads Boston Scientific’s growth and market-innovation initiatives across all business units of BSC. He is responsible for intensifying the companies’ commercial impact. His current priorities are developing partnerships with large healthcare systems (IDNs) around the globe by deploying innovative solutions to reduce healthcare cost and improve quality. Corporate sales, marketing, commercial operations, and solutions report into Mark.

Mark has been in the medical device space for over 20 years. Previously, he served as Senior Vice President of BSC’s Interventional Cardiology, Cardiac Rhythm Management, Peripheral Interventions, and Electrophysiology divisions, overseeing over 2000 employees in sales, commercial operations, and customer service. He was accountable for over $4B in revenue and led the integration efforts of key acquisitions, such as Guidant Corporation, Cameron Health (S-ICD), Bridgepoint Medical (CTO), and Watchman (LAAC) that has helped propelled the company back to growth.

Mark is a member of Boston Scientific’s management board, investment board, global compliance board, and political action board. He also serves on numerous industry boards and has been a faculty member/speaker at numerous medical conferences. He graduated from the University of Louisville where he played 4 years of college golf for the Cardinals. Mark, his wife Robyn and their three children have been residents of the Twin Cities since 2003.



Scott R. Ward

Board of Directors, USA

Mr. Ward is a Managing Director at SightLine Partners. Mr. Ward has over 30 years of experience in the healthcare industry, including 15 years as an operating business leader. He was most recently Senior Vice President and President of the CardioVascular business of Medtronic Inc., responsible for all worldwide operations of the CardioVascular Business including the Coronary, Peripheral, Endovascular, Structural Heart Disease and Revascularization and Surgical Therapies Businesses. Previously, Mr. Ward served as Senior Vice President and President of Medtronic Neurological and Diabetes, with responsibility for the global Neurological, Neurologic Technologies, Diabetes, Gastroenterology and Urology businesses; Vice President and General Manager of the Medtronic Drug Delivery Business; and Director of Medtronic NeuroVentures. Mr. Ward is the Founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services. He is Chairman of the Board of Cardiovascular Systems and Creganna-Tactx Medical Devices. He also serves on the Board of Impedimed, Inc and numerous venture stage medical technology companies.



Robert O. Bonow, MD, MS

Board of Directors, USA

Dr. Robert O. Bonow is the Goldberg Distinguished Professor of Cardiology at the Northwestern University Feinberg School of Medicine, where he is Vice Chairman of the Department of Medicine and Director of the Center for Cardiovascular Innovation. He received his MD degree from the University of Pennsylvania School of Medicine. His past positions include Senior Investigator at the National Heart Lung and Blood Institute from 1980 to 1992, where he was Deputy Chief of the Cardiology Branch, and Chief of the Division of Cardiology at Northwestern University from 1992 to 2011. He has authored or co-authored 510 papers in the medical literature and 110 book chapters. He serves on the editorial boards of 12 medical journals and is one of the four editors of Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine.

Dr. Bonow is past-President of the American Heart Association, a Master of the American College of Cardiology and a Master of the American College of Physicians. He has served on the Board of Trustees of the American College of Cardiology, the Board of Directors of the American Heart Association, the Subspecialty Board on Cardiovascular Disease of the American Board of Internal Medicine, the Board of Extramural Advisors of the National Heart, Lung and Blood Institute, and the Clinical Research Roundtable of the Institute of Medicine.

Among his honors are the NIH Director’s Award, the U.S. Public Health Service Commendation Medal and Outstanding Service Medal, and elected membership in the American Society for Clinical Investigation and the Association of American Physicians. He is the recipient of the Distinguished Leadership Award, Distinguished Achievement Award, Gold Heart Award, and James B. Herrick Award of the American Heart Association; the Distinguished Fellowship Award and Distinguished Service Award of the American College of Cardiology; the Denolin Award of the European Society of Cardiology; and the John Phillips Memorial Award of the American College of Physicians. An endowed chair was established in his name at Northwestern University in 2012.



Raymond Woosley, MD, PhD

Board of Directors, USA

Raymond L. Woosley, MD, PhD, is a Flinn Scholar and professor of Biomedical Informatics and Medicine at the University of Arizona College of Medicine – Phoenix. He is also the founding president and chairman of the Board for AZCERT, Inc., a non-profit organization funded by the U.S. Food & Drug Administration (FDA) to work with the College of Medicine to improve the safe use of medications.

Dr. Woosley received his medical degree from the University of Miami in Florida, his doctorate in pharmacology from the University of Louisville in Kentucky, and his bachelor’s degree from Western Kentucky University. After an internship and residency in internal medicine, he completed a fellowship in clinical pharmacology at Vanderbilt University before joining the faculty as founding director of the Vanderbilt Cardiac Arrhythmia Center and rose to the rank of professor of Medicine and Pharmacology and associate director of the Vanderbilt Clinical Research Center.

In 1988, Dr. Woosley was appointed chairman of the Department of Pharmacology at Georgetown University Medical Center in Washington, D.C. He also served as associate dean for Clinical Research and director of the Institute for Cardiovascular Sciences. In 2001, Dr. Woosley joined the faculty at the University of Arizona as vice president of the Arizona Health Sciences Center and the dean of the College of Medicine. In 2005, he founded Critical Path Institute (C-Path), an independent, non-profit organization created jointly by the FDA and the University of Arizona to help implement the FDA’s Critical Path Initiative and accelerate the development of new drugs and diagnostics. In 2012, he founded the non-profit AZCERT, Inc.

Dr. Woosley’s research has been reported in more than 300 peer-reviewed publications and serves as the basis for 11 patents. For his contributions to medicine, Dr. Woosley has received numerous awards and honors from academic institutions, the FDA, and professional societies.



Louis B. Jacques, MD

Board of Directors, USA

Louis B. Jacques, MD, is Chief Clinical Officer and a Senior Vice President at ADVI, where he is also a partner. ADVI is a health care advisory services firm with offices in Washington DC, Austin, and San Francisco. Before joining ADVI in 2014, Dr. Jacques was the Director of the Coverage and Analysis Group (CAG) in the Centers for Medicare & Medicaid Services (CMS) from 2009 – 2014, where he managed Medicare fee for service coverage policy development on technologies as diverse as molecular diagnostic testing, advanced imaging, chemotherapeutics, wound care, and screening and preventive services. From 2004 – 2009 he was a division director within CAG.

Before joining CMS in 2003, he served as the Associate Dean for Curriculum at Georgetown University School of Medicine; where he also saw patients at the Lombardi Cancer Center in his practice of hospice and palliative medicine. Jacques also made volunteer home visits for a hospice on Maryland’s Eastern Shore. While in active clinical practice he was a diplomate of both the American Board of Hospice and Palliative Medicine and the American Board of Family Medicine. He recertified his Family Medicine boards in 2013.

Louis earned his undergraduate degree in 1978 from Georgetown University and his MD in 1982 from the University of Maryland. After completing his residency in family practice he served in a National Health Service Corps assignment in a Waterloo Iowa community health clinic. Before returning to the Washington DC area he worked in Detroit with the Henry Ford Medical Group and joined the faculty of the Wayne State University School of Medicine.



Jeroen Bax, MD

Board of Directors, The Netherlands
ISCTR Liaison to the European Society of Cardiology

Jeroen J. Bax, MD, PhD, is Professor of Cardiology and Director of Noninvasive Imaging at Leiden University Medical Center in Leiden, The Netherlands, where he received his medical degree and cardiology training. Dr. Bax received his PhD from the Free University in Amsterdam, where he supervised the thesis of 26 PhD fellows.

President-Elect of the European Society of Cardiology, Dr. Bax has long served the ESC in numerous capacities, including chair of the Cardiology Practice Guidelines Committee, Chair of the Scientific Program, Co-Chair of two International Conferences on Nuclear Cardiology, Chair of the Press Committee, and Co-Editor of two books on cardiac imaging. Dr. Bax continues to serve as Co-Director of the ETP course on Nuclear Cardiology, a position he has held since 2003. He is a Fellow of the ESC as well as the American College of Cardiology and the American Society of Nuclear Cardiology. In 2008, Dr. Bax was honored with a Silver Medal from ESC and the Douglas P. Zipes Award from ACC.

Currently an Associate Editor of the European Heart Journal and a Section Editor for UptoDate, Dr. Bax sits on the editorial boards of five additional professional journals and previously was an Associate Editor for the Journal of the American College of Cardiology. Widely published, Dr. Bax’s major research interest is in applying various noninvasive imaging techniques in clinical cardiology, including coronary artery disease, arrhythmias, and heart failure.


Professor Alain Cribier, MD, FACC

Board of Directors, Europe

Prof. Alain Cribier, MD, FACC, became widely recognized for having developed new interventional technologies for the treatment of valvular heart diseases: balloon aortic valvuloplasty in 1985; mitral commissurotomy in 1994; and, after 15 years of research, the transcatheter implantation of aortic valves (TAVI), performing the first world case in Rouen in 2002. This last breakthrough technology is now widely used in the world, with more than 300,000 patients treated and an explosive growth that will have a durable impact on the pattern of medical practice.

Prof. Cribier completed his medical studies at the Paris University of Medicine and served his residency and fellowship at Rouen University Hospital as well as a fellowship at Cedars-Sinai Medical Center in Los Angeles. He joined the cardiology department at the university, where he served as the Chief of Cardiology for 20 years. Currently Professor Emeritus at the university, Prof. Cribier serves as Medical Director of the Rouen Normandy Medical Training Center, a multidisciplinary center dedicated to teaching and learning medicine through simulation, video-conferences and training between surgeons, physicians and experts.

Prof. Cribier has published more than 1,500 journal articles and received numerous degrees, awards and recognitions for his lifelong dedication and contributions to interventional cardiology. These include the Andreas Grüntzig and Laennec Awards from the French Society of Cardiology, the Euro-PCR Ethics Award, the TCT Career Achievement award, the Maeri Florio Lecture Award, the Ray C. Fish Award, Legend of Medicine Award, and the ESC Gold Medal. He has been knighted with the Chevalier de l’Ordre de la Légion d’Honneur (Legion of Honor), Chevalier de l’Ordre des Palmes Académiques (Academic Palms), and in June 2017 received a Grand Prize from the Institut de France Foundation: the Lefoulon-Delalande award for his “minimally invasive technique of interventional cardiology replacing aortic valves by simple catheter.”


Martin B. Leon, MD

Board of Directors, USA

The Director and Founder of TCT, Martin B. Leon, MD, is Professor of Medicine at Columbia University Medical Center, Director of the Center for Interventional Vascular Therapy, Director of the Cardiac Catheterization Laboratories, and on the Executive Board of the Columbia NewYork-Presbyterian Heart Valve Center. Dr. Leon is also the Founder and Chairman Emeritus of the Cardiovascular Research Foundation. Dr. Leon has served as principal investigator for more than 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, including the PARTNER trials on transcatheter valve therapy for patients with aortic stenosis. Recognized with 10 international career achievement awards, Dr. Leon has co-authored more than 1,550 publications, performed more than 10,000 interventional procedures, led more than 100 international educational programs in interventional cardiology, and had a major impact as a thought leader and innovator in interventional cardiovascular device and drug therapies.

Dr. Leon completed a fellowship in Cardiology at the Yale-New Haven Hospital. He completed medical school at the Yale School of Medicine, and his internship and residency in internal medicine at the Yale-New Haven Hospital. He was previously the Director of Cardiovascular Research and Education at the Lenox Hill Heart and Vascular Institute in New York and the Director of Clinical Research at the Washington Cardiology Center at the Washington Hospital Center and Clinical Professor of Medicine at Georgetown University Medical Center in Washington, DC. Earlier in his career, he served as a Clinical Associate, Senior Investigator, and Director of the Catheterization Laboratories in the Cardiology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health.


Ian Meredith, MD

Board of Directors, USA

Ian Meredith, MD, is Global Chief Medical Officer and Executive Vice President of Boston Scientific. He previously served as professor of medicine and cardiology for Monash University, Director of MonashHeart and Monash Health and as executive director of the Monash Cardiovascular Research Centre in Melbourne, Australia.

He has performed more than 10,000 invasive cardiac and coronary procedures, published more than 300 manuscripts and has been chief or principal investigator on 30 major international multi-center trials, including first-in-man trials of new drug-eluting stents. Dr. Meredith’s work has focused on the development and clinical evaluation of devices for the treatment of coronary artery and structural heart disease, and he has been at the forefront of emerging percutaneous cardiac valve therapies.

Professor Meredith received undergraduate and doctorate degrees from Monash University in Melbourne, Australia. He trained in Melbourne and completed his PhD at the Baker Institute before spending 3 years at the Brigham & Women’s Hospital and Harvard Medical School in Boston.